"Highy sensitive and specific low-cost lab-on-chip system for lyme disease diagnosis" “Promoting Active Ageing: Functional Nanostructures for Alzheimer’s disease at ultra-early stages” Designation of the project | spinit-crispr Approval date | 19-02-2019 Project summary Strategic goals Objectives, activities and expected / achieved results
FP7 - NMP - Collaborative Project
Grant Agreement nº 212043
The NAD (Nanoparticles for therapy and diagnosis of Alzheimer's disease) Project is aiming to develop nanoparticles for Alzheimer's diagnosis and therapy. The research is financed by the European Union's 7th Framework Program and includes 19 European research centers.
Grant agreement no: CP-IP 212043-2 NAD. Prof. Masserini of University of Milano-Bicocca is the scientific coordinator of the project.
Recent statistics indicate that 24.3 million people worldwide are affected by dementia with 4.6 million new cases per year (one new case every 7 seconds). In Europe there are 5 million cases of dementia, 3 million of which are classified as Alzheimer's. Given the continuing increase in life expectancy, these numbers are expected to rise dramatically. In 2040 cases are expected to double in Western Europe and to triple in Eastern Europe. Despite great progress in the scientific field, which has made interpretation of the molecular bases of the disease possible, there has been little progress in diagnosis and therapy.
The goal of the study, developed in the field of nanotechnologies, is to create nanoparticles (NPs) able to cross the blood-brain barrier to reach the brain, principal site of Alzheimer's disease. Molecules that can recognize (diagnosis) and destroy (therapy) the amyloid deposits, characteristic of the illness, will be attached to the nanoparticles, and tested on animal models of the disease (transgenic mice). If the expectations of the research are attained, future experiments can be performed on humans. The results can have an enormous impact on the early diagnosis and therapy of a disease of high incidence, which takes a heavy social cost.
FP7 - Research for the benefict of SMEs
Grant Agreement nº: 262411
The aim of HILYSENS is to develop a novel lab-on-chip diagnostic tool to improve clinical diagnostic, disease monitoring and treatment of Lyme disease by enabling specific and sensitive detection of the human serological response against its causative agent: Borrelia burgdoferi. Lyme Disease is the most common tick-borne infection in Europe with around 85,000 new cases per year and its incidence is increasing due to climate change. Current laboratory diagnostic methods lack sensitivity and specificity to detect early cases as well as late manifestations of the disease such as chronic or autoimmune-related infections. For this reasons, disease incidence is underestimated as many cases go mis- or undiagnosed. Late, delayed, or inadequate treatment can lead to serious symptoms such as neuroborreliosis or arthritis, which can be disabling and difficult to treat.
HILYSENS will develop a specific multi-antigen assay in a lab-on-a-chip device to detect Borrelia infections.
European Union’s Horizon 2020 - Research and Innovation Programme
Grant Agreement nº: 686009
“STAB VIDA is happy to be part of the H2020’s PANA project – “Promoting Active Ageing: Functional Nanostructures for Alzheimer’s disease at ultra-early stages” - a project conducted by a consortium of 11 partners from different countries across Europe and coordinated by “Servizo Galego de Saude (SERGAS)”.
Project Code | POCI-01-0247-FEDER-033778
Main goal | Reinforce research, technology development and innovation
Region of activity | Lisboa
Beneficiary | biosurfit, S.A./ IPATIMUP – Instituto de Patologia e Imunologia Molecular da Universidade do Porto/ Stab Vida - Investigação e Serviços em Ciências Biológicas, Lda
Start date | 01-06-2019
End date | 31-05-2022
Total eligible value | 1.364.174,44 €
EU Financing | 862.527,86 €
On a co-promotion initiative, the project presents the development of a rapid diagnostic test panel of Dengue, Zika and Chikungunya febrile syndromes. The grant supports all R&D developments and the translation of multiplexed molecular isothermal amplification techniques to a lab-on-a-disc device and subsequent analytical and clinical validation.
Main objective | To strngthen the competitiveness of SMEs
Intervention region | Lisbon
Beneficiary | STAB VIDA, Investigação e Serviços em Ciências Biológicas
Approved on | 17-07-2020
Start date | 27-04-2020
Completion date | 16-09-2020
Total eligible cost | € 470,125.90
European Union financial support | FEDER: € 446,619.61
(A) Diagnostic and analysis of COVID-19;
(B) Characterization and viral genomic analysis of SARS-CoV-2; and
(C) Characterization of individual and collective immunity to COVID-19.
"Highy sensitive and specific low-cost lab-on-chip system for lyme disease diagnosis"
“Promoting Active Ageing: Functional Nanostructures for Alzheimer’s disease at ultra-early stages”
Designation of the project | spinit-crispr
Approval date | 19-02-2019
Objectives, activities and expected / achieved resultsSTAB4COVID project foresees the battle of the pandemic COVID-19 through the provision of :